Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 3/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7203812 | 0.84 | CYP19A1 (0.62) | ALDH1A1ALOX15TSHRMEN1KMT2A | |
| SCHEMBL9265700 | 0.84 | ALDH1A1 (0.60) | ALDH1A1ALOX15TSHRMEN1KMT2A | |
| SCHEMBL593064 | 0.84 | CYP19A1 (0.62) | ALDH1A1ALOX15TSHRMEN1KMT2A | |
| SCHEMBL1172437 | 0.84 | CYP19A1 (0.55) | ALDH1A1ALOX15TSHRMEN1KMT2A | |
| SCHEMBL69389 | 0.84 | ALDH1A1 (0.60) | ALDH1A1ALOX15TSHRMEN1KMT2A | |
| Fluoride SCHEMBL27574861 | 0.81 | CYP19A1 (0.59) | ALDH1A1ALOX15TSHRMEN1KMT2A | |
| Water SCHEMBL28180935 | 0.81 | CYP19A1 (0.59) | ALDH1A1ALOX15TSHRMEN1KMT2A | |
| SCHEMBL30387741 | 0.81 | CYP19A1 (0.59) | ALDH1A1ALOX15TSHRMEN1KMT2A | |
| SCHEMBL29381787 | 0.81 | CYP19A1 (0.59) | ALDH1A1ALOX15TSHRMEN1KMT2A | |
| SCHEMBL11025543 | 0.77 | CYP19A1 (0.50) | ALDH1A1ALOX15TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583815-B2 | Inhibitors of YAP/TAZ-TEAD oncoproteins, synthesis and use thereof | BRIDGENE BIOSCIENCES, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4631573-A2 | TEAD INHIBITORS | Orion Corporation (FI) | 2025-10-15 | — | — | EP | disclosed |
| EP-4323338-B1 | TEAD INHIBITORS | ORION CORP (FI) | 2025-10-08 | — | — | EP | disclosed |
| US-12391663-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-19 | — | — | US | disclosed |
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250136558-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | BIOMEA FUSION, INC. | 2025-05-01 | — | — | US | disclosed |
| US-20240294495-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-05 | — | — | US | disclosed |
| US-20240287059-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2024-08-29 | — | — | US | disclosed |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-08 | — | — | US | disclosed |
| US-20240246908-A1 | TEAD INHIBITORS | ORION CORPORATION (FI) | 2024-07-25 | — | — | US | disclosed |
| CN-1262547-C | Phenyl-and aminophenyl-alkyl sulfonamide and urea derivative | HOFFMANN LA ROCHE (CH) | 2006-07-05 | — | — | CN | disclosed |
| CN-1176910-C | Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives | - | 2004-11-24 | — | — | CN | disclosed |
| CN-1515559-A | Phenyl-and aminophenyl-alkyl sulfonamide and urea derivative | - | 2004-07-28 | — | — | CN | disclosed |
| CN-1515562-A | Phenyl-and aminophenyl-alkyl sulfonamide and urea derivative | - | 2004-07-28 | — | — | CN | disclosed |
| EP-1420018-A1 | Pyrido[1,2-a]benzimidazole derivatives useful in treating central nervous system disorders | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-05-19 | — | — | EP | disclosed |
| US-6057349-A | ALPHA.SUB.1A/1L AGONISTS USED IN THE TREATMENT OF VARIOUS DISEASE STATES SUCH AS URINARY INCONTINENCE, NASAL CONGESTION, PRIAPISM, DEPRESSION, ANXIETY, DEMENTIA, SENILITY, ALZHEIMER'S, DEFICIENCIES IN ATTENTIVENESS AND COGNITION, AND | F. HOFFMAN LA ROCHE AG (CH) | 2000-05-02 | — | — | US | disclosed |
| US-5952362-A | INHIBITOR OF GLYCOGEN PHOSPHORYLASE ENZYMETIC ACTIVITY AND GLUCOSE ACITIVITY | SYNTEX (U.S.A) INC. (US) | 1999-09-14 | — | — | US | disclosed |
| EP-0887346-A2 | Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives, their preparation and their use as alpha1A/1L adrenoceptor agonists | F. HOFFMANN-LA ROCHE AG (CH) | 1998-12-30 | — | — | EP | disclosed |
| CN-1203228-A | Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives | HOFFMANN LA ROCHE (CH) | 1998-12-30 | — | — | CN | disclosed |
| EP-0863142-A1 | Heterocyclic herbicides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | ALDH1A1 2205/4885ALOX15 3189/4885TSHR 4733/4885 |
| US-20250136558-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | FLT3, MCL1, JAK2 | ALDH1A1 1930/4885ALOX15 4568/4885TSHR 1908/4885 |
| US-12583815-B2 | Inhibitors of YAP/TAZ-TEAD oncoproteins, synthesis and use thereof | YAP1, TEAD1, TEAD2 | ALDH1A1 3155/4885ALOX15 3522/4885TSHR 1551/4885 |
| US-12391663-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | ALDH1A1 1142/4885ALOX15 3529/4885TSHR 1114/4885 |
| US-20240294495-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CRBN, GSPT1, GSPT2 | ALDH1A1 4056/4885ALOX15 3374/4885TSHR 2591/4885 |
| US-20240246908-A1 | TEAD INHIBITORS | TEAD3, TEAD1, TEAD2 | ALDH1A1 630/4885ALOX15 2476/4885TSHR 628/4885 |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MYC, MYCBP, GSPT1 | ALDH1A1 4276/4885ALOX15 4496/4885TSHR 2333/4885 |
| US-20240287059-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | ALDH1A1 2205/4885ALOX15 3189/4885TSHR 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.